BioWorld Asia

April 23, 2003

Celltech Brings On New CEO Following Purchase Of OGS

LONDON - It was all change last week as members of the Oxford GlycoSciences plc board resigned to make way for directors from its new owner, Celltech Group plc, and Celltech announced the appointment of its new CEO, Goran Ando. (BioWorld International) Read More

Gamma Capital Bucks Austrian Trend, Closes New Venture Round

Recombinant BCG Boosts TB Protection In Animal Studies

Affibody, InforSense Release Tool For Data Interpretation

CeNeS Sells Three Products To Strengthen Cash Position

Cellectis Licenses Technology To Nucleis For Gene Insertion

Oxford BioMedica Cuts Back On Programs To Extend Cash

Progress In Two Early Programs Gives Xenova Much-Needed Lift

French Researchers Find Gene Linked To Kindler's Syndrome

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2026.

Alicorn synthesizes new AAK1 inhibitors

BioWorld Science

Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...

GLP-1s need technologies for long-term use

BioWorld

For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...

Illustration of glucose in the blood stream

CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research

BioWorld Science

Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...

HMNC raises $50M series B to prep depression drugs for phase III

BioWorld

HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...